CPRX
CatalystANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The standstill around the $31.50 cash deal limits upside, but Q1 operating results still showed a functioning commercial franchise, and the FIRDAPSE settlement reduced legal noise ahead of close [#10-Q-2026-05-11] [#8-K-2026-05-07].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.2.
What can break
If the Angelini transaction fails, the stock could reprice sharply lower on a standalone basis.
Momentum
87
Value
67
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.50 · Bull $31.60 · Bear $26.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $34.00
Why
Momentum87 · Δ7d -4.2
Value67 · Δ7d +0.2
Sentiment46 · Δ7d +1.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-0.8
Value
67
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.4
Sentiment
46
33% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
+10.8
Why this grade
Composite grade A. Momentum 86.8 / Value 66.8 / Sentiment 46.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.83B
Beta
0.73
Shares Out
122.91M
P/E (TTM)
13.3
P/S (TTM)
4.85
P/FCF (TTM)
11.95
Rev YoY
+15.3%
EPS YoY
+18.7%
Gross Margin
+85.7%
Op Margin
+44.8%
Net Debt
-$517.55M
Current Ratio
6.62
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology